Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Chiroscience fills war chest

OXFORD - Chiroscience Group plc ended months of speculation over what it would do with its chiral services business, agreeing to sell 30 percent of its chiral products and services subsidiary Chirotech Technology Ltd. to conglomerateAscot Plc for £30 million in cash.

The cash will allow Chiroscience (LSE:CRO; Cambridge, U.K.) both to avoid the equity markets and to

Read the full 575 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers